Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Barclays analyst Peter Lawson downgrades Exscientia (NASDAQ:EXAI) from Overweight to Equal-Weight and announces $5 price tar...
TD Cowen analyst Brendan Smith downgrades Exscientia (NASDAQ:EXAI) from Buy to Hold.
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industria...
Expect 10 Clinical Readouts In 18 Months, $200M In Milestone Payments Over 24 Months, $20B Potentially Overall, $850M Cash On H...
Barclays analyst Peter Lawson maintains Exscientia (NASDAQ:EXAI) with a Overweight and lowers the price target from $10 to $9.
The monotherapy dose escalation phase of ELUCIDATE is designed to assess the safety, pharmacokinetics and pharmacodynamics of &...
The platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to ...
TD Cowen analyst Brendan Smith initiates coverage on Exscientia (NASDAQ:EXAI) with a Buy rating.
